Quantcast

Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

August 19, 2014

– Two of Company’s Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C. difficile –

ROCKVILLE, Md., Aug. 19, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO

Synthetic Biologics’ Senior Vice President, Research & Development, Mike Kaleko, M.D., Ph.D., will present a late-breaking poster related to the Company’s C. difficile program. The poster will be available for viewing in Exhibit Hall A on Saturday, September 6, from 12:00pm to 2:00pm Eastern Time, as part of the “Agents Targeting Clostridium difficile” session.

Title: P4A, a Novel Oral Beta-Lactamase for the Prevention of Cephalosporin-Induced C. difficile Infection
Authors(1): M. Kaleko, J. A. Bristol, S. Connelly, P. Koski
Poster: F-250c

“We are thrilled to have the opportunity to present research from our novel C. difficile program at ICAAC. This conference is known for its high academic standards and draws the infectious disease field’s foremost leaders. We look forward to presenting our findings that support the development of our prophylactic to protect the GI microflora from the effects of certain IV antibiotics for the prevention of C. difficile infection,” stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “This scientific presentation is very relevant, as we continue to advance our innovative C. difficile program toward clinical trials during 2014.”

The Company previously announced that Synthetic Biologics’ academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin’s McKetta Department of Chemical Engineering will highlight Synthetic Biologics’ SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis (whooping cough) in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the “Neonatal Infections and the Case for Maternal Immunization” session.

Title: Rational Design of Antibody Cocktails to Treat Disease Caused by Bordetellae
Authors: M. Kaleko(1), A. Nguyen(2), E. Wagner(2), J. Laber(2), L. Goodfield(3), W. Smallridge(3), E. T. Harvill(3), R. F. Wolf(4), J. C. Papin(4), J. A. Maynard(2)

(1)Synthetic Biologics, Rockville, MD, (2)Universty of Texas at Austin, Austin, TX, (3)Penn State Univ., University Park, PA, (4)Univ. of Oklahoma Hlth. Sci. Ctr., Oklahoma City, OK

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Synthetic Biologics’ continued advancement of its C. difficile program toward clinical trials. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the additional clinical studies and results not meeting expectations and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Logo – http://photos.prnewswire.com/prnh/20130522/MM19465LOGO

SOURCE Synthetic Biologics, Inc.


Source: PR Newswire



comments powered by Disqus